Navigation Links
Biosimulation Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
Date:12/29/2012

Albany, NY (PRWEB) December 29, 2012

Biosimulation is computer aided mathematical simulation of biological systems and processes. Biosimulation is used for model based calculation of biological systems. The global biosimulation market is expected to grow at a considerable rate from 2011 to 2018. The primary reason for the growth of biosimulation is the increasing use of pharmacodynamic and pharmacokinetic (PKPD) modeling in pre-clinical drug development. PKPD is the most widely used method in drug development.

Related Report: Surgical Equipment Market

Increasing importance of advanced techniques to reduce the drug development and discovery cost is the primary factor for the growth of the global biosimulation market. Also, increased spending on health care, advanced computer technology, improved simulation and modeling tools will also contribute to the growth of the biosimulation market. Lack of standardization in biosimulation methodology, lack of knowledge about biological processes and systems and risk of failing of drugs in biosimulation are the major hurdles for this market. However, innovative technology will help to overcome these barriers.

Based on application, the biosimulation market could be segmented into two major categories--drug discovery and drug development. Drug discovery is further segmented into target identification, lead identification, target validation, and lead optimization. Drug development biosimulation is segmented into pre-clinical testing and clinical trial. The global market for biosimulation could be segmented into North America, Europe, Asia-Pacific, and Rest of the World (ROW).

Related Report: http://www.transparencymarketresearch.com/us-vaccine-market.html

North America is the largest regional market by revenue for biosimulation and holds more than one third of the global biosimulation market share. Europe is the second largest regional market and represents the fastest growing regional market for the biosimulation industry. Growth in the European market is due to efforts of regulatory bodies in promoting advanced technologies in drug discovery and development. The biosimulation market in Asia is at a development stage and growing at a relatively slower rate due to lack of skilled workers and infrastructure facilities.

Some of the major players in this industry include Schrodinger, Accelrys, Certara, Rhenovia, Simulation Plus, ACD/Labs, LeadScope, CCG, Entelos, Physiomics, Genedata, Insilico Biotechnology, Archimedes, Insilico biosciences and Compugen.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
North America
Asia Pacific
Europe
Rest of the World

This report provides comprehensive analysis of:
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Related Report: http://www.transparencymarketresearch.com/prostat-cancer-minimal-invasive-surgery-market.html

Reasons for Buying this Report:
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a technological growth map over time to understand the industry growth rate
It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides an overview of the pricing trend and its impact on the market

Visit: http://www.transparencymarketresearch.com/

Read the full story at http://www.prweb.com/releases/2012/12/prweb10279958.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The J. Rich Company Capitalizes on Tenants’ Office Market for Non-Profit Client, Albany Park Community Center
2. Xoçai™ Activ, A Delicious, Healthy, Active-lifestyle Antioxidant Beverage Has Been Released by Marketing Xocolate International Corporation (MXI Corp)
3. Marketing Xocolate International Corporation (MXI Corp) Unveils New Healthy Dark Chocolate Product: Xoçai™ Nuggets, Which Are Both Diabetic And Vegan Friendly
4. CGJ-Shop Introduced its Winter Jacket 2013 Collection, and Launched a Promotion to Expand its Online Market Share
5. Grape News: Global Wine Manufacturing Industry Market Research Report from IBISWorld has Been Updated
6. Marketing Xocolate International Corporation (MXI-Corp) Introduces Xe Healthy Energy Drink, A Rich And Delicious Antioxidant Beverage, Now Added to Xoçai™ Product Line
7. Fuel Additives Market Growing at CAGR of 6% to Reach $6,401 Million by 2017 - New Report by MarketsandMarkets
8. North American Region Displays Highest Growth Rate at a CAGR of 9.2% Over the Next Five Years in Cyber Security Market by MarketsandMarkets
9. Marketing Xocolate International Corporation Sponsors The Xo-Love Project, An International Humanitarian Effort, to Increase Charitable Donations And Community Outreach
10. iTrade Capital Markets, ICM Trading Offers Investors an Opportunity to Become a Partner With iTrade Capital Markets
11. iTrade Capital Markets/ICM Trading is Now Offering Opportunity to Open a No-Cost Practice Trading Account
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: